Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Growth in Short Interest

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 6,620,000 shares, an increase of 5.2% from the January 15th total of 6,290,000 shares. Based on an average daily trading volume, of 12,710,000 shares, the short-interest ratio is currently 0.5 days. Currently, 8.8% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research note on Monday, February 3rd. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Invivyd in a research report on Tuesday, February 4th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Morgan Stanley cut their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $7.89.

Insider Transactions at Invivyd

In other news, Director Terrance Mcguire sold 86,545 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the transaction, the director now directly owns 3,170,231 shares of the company’s stock, valued at approximately $1,521,710.88. This trade represents a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last three months, insiders have sold 816,466 shares of company stock valued at $423,214. Corporate insiders own 17.90% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Hedge funds and other institutional investors have recently bought and sold shares of the company. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd during the third quarter valued at about $27,000. Jane Street Group LLC increased its position in shares of Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after acquiring an additional 87,358 shares during the last quarter. Barclays PLC increased its position in shares of Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company’s stock valued at $56,000 after acquiring an additional 9,207 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Invivyd during the fourth quarter valued at about $74,000. Finally, JPMorgan Chase & Co. increased its position in shares of Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after acquiring an additional 222,375 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Trading Up 16.7 %

Invivyd stock traded up $0.23 during midday trading on Monday, hitting $1.61. 7,174,796 shares of the stock were exchanged, compared to its average volume of 36,383,976. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $4.74. The stock has a market capitalization of $192.59 million, a price-to-earnings ratio of -0.82 and a beta of 0.61. The stock’s 50-day simple moving average is $0.70 and its 200 day simple moving average is $0.85.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.